Jim Cramer's Top Takeaways: Johnson & Johnson, Expedia

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.

Johnson & Johnson (JNJ) : Cramer sat down with Alex Gorsky, chairman and CEO of Johnson & Johnson and a retired army captain, to talk business, politics and the many advantages of hiring veterans.

Thursday's show, ahead of Veterans Day, was shot before a studio audience of West Point Cadets, veterans, military personnel and their families.

Gorsky said of the 45,000 Johnson & Johnson employees currently in the U.S., more than 5% of them are veterans. He said, "We couldn't do what we do without the great work of veterans" that provide leadership and problem-solving skills the company needs. Johnson & Johnson makes hiring veterans a priority and trains recruiters on how to translate military skills into workforce assets.

Gorsky also noted his involvement in the Travis Manion Foundation, which aims to help veterans and the families of fallen veterans. He said the foundation proves that our country is always stronger together.

When asked about this year's political season, which has vilified the pharmaceutical industry, Gorsky said that health care is important and it's an important part of our economy, so it deserves to be part of the debate. But, he said, it's important to remember all of the good that pharma brings and the many diseases it cures and not just focus on the problems that still need to be solved.

Real Money: Mark Newton has 5 health-care stocks set to bounce 

Read Jim Cramer's interview with Starbucks CEO Howard Schultz.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Some of Trump's NFL Owner Friends Side With Players in Dispute With President

The Best Companies for Women

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'